Feb 20, 2020
Immune checkpoint inhibitors have revolutionized cancer
treatment. Unlike chemotherapy, which essentially includes cellular
toxins that can cause widespread and unnecessary tissue damage,
checkpoint inhibitors are used to train the body’s natural immune
system to fight off the cancer. And while they are extraordinarily
effective options for patients with malignant disease, they are not
without risk. Every day, we are learning more and more about the
autoimmune side effects of these novel therapies.
This week on the BrainWaves Podcast, Dr. Justine Cohen
(University of Pennsylvania) shares her experience managing
patients with checkpoint inhibitor neurotoxicity.
Produced by James E. Siegler and Justine Cohen. Music courtesy
of Jon Watts, Kai Engel, and Kevin McLeod--as well as a cameo
appearance by the Checkpoints. Unless otherwise mentioned in the
podcast, no competing financial interests exist in the content of
this episode. Sound effects by Mike Koenig and Daniel Simion.
BrainWaves' podcasts and online content are intended for medical
education only and should not be used for clinical decision making.
Be sure to follow us on Twitter @brainwavesaudio for the latest
updates to the podcast.
- Bhatia S, Tykodi SS and Thompson JA. Treatment of metastatic
melanoma: an overview. Oncology (Williston Park).
- Hottinger AF. Neurologic complications of immune checkpoint
inhibitors. Curr Opin Neurol. 2016;29:806-812.
- Wick W, Hertenstein A and Platten M. Neurological sequelae of
cancer immunotherapies and targeted therapies. Lancet
- Cohen JV and Buchbinder EI. The Evolution of Adjuvant Therapy
for Melanoma. Curr Oncol Rep. 2019;21:106.
- Cohen JV, Wang N, Venur VA, Hadfield MJ, Cahill DP, Oh K and
Brastianos PK. Neurologic complications of melanoma.
Cancer. 2019. Epub ahead of print.
- Graus F and Dalmau J. Paraneoplastic neurological syndromes in
the era of immune-checkpoint inhibitors. Nat Rev Clin
- Zekeridou A and Lennon VA. Neurologic Autoimmunity in the Era
of Checkpoint Inhibitor Cancer Immunotherapy. Mayo Clinic
- Zubiri L, Allen IM, Taylor MS, Guidon AC, Chen ST, Schoenfeld
SR, Neilan TG, Sise ME, Mooradian MJ, Rubin KM, Leaf RK, Parikh AR,
Faje A, Gainor JF, Cohen JV, Fintelmann FJ, Kohler MJ, Dougan M and
Reynolds KL. Immune-Related Adverse Events in the Setting of
PD-1/L1 Inhibitor Combination Therapy. Oncologist. 2019.
Epub ahead of print.